Últimas noticias sobre Kimberly-Clark (NASDAQ:KMB) Bolsa

KIMBERLY-CLARK CORP

Kimberly-Clark

With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, PullUps, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.

Kimberly-Clark Corporation - Common Stock

Kimberly-Clark Corp

KAMBI GROUP LTD ORD B by Kambi Group LTD.

Kambi Group PLC

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>Lululemon Athletica Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) stock dipped 16.23% after the company reported first-quarter results and<a href="https://www.benzinga.com//node/45819605" target="_blank" rel="noreferrer noopener"> analysts revised the price forecast</a>.</li>
<li>Brown Forman Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) shares tumbled 15.69% after the company reported <a href="https://www.benzinga.com//node/45793814" target="_blank" rel="noreferrer noopener">worse-than-expected financial results</a> due to the trade war and tariffs. Analysts lowered the price <a href="https://www.benzinga.com/quote/bf-b/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast on the stock</a>.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) shares declined 15.04% after the company reported first-quarter results and analysts <a href="https://www.benzinga.com//node/45818750" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock decreased 14.81%, possibly due to Elon Musk&#8217;s departure from the White House and his ongoing <a href="https://www.benzinga.com//node/45805173" target="_blank" rel="noreferrer noopener">feud with President Trump</a>.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares fell 9.17% after reporting worse-than-expected <a href="https://www.benzinga.com//node/45788812" target="_blank" rel="noreferrer noopener">second-quarter results</a>. Several analysts revised <a href="https://www.benzinga.com//node/45822276" target="_blank" rel="noreferrer noopener">the price forecast</a> for Ciena stock.</li>
<li>Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) stock dived 8.97%.</li>
<li>Kimberly-Clark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>) shares were down 7.10%. Last week, Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) rolled up $3.4 billion in <a href="https://www.benzinga.com//node/45797473" target="_blank" rel="noreferrer noopener">a tissue deal with Kimberly-Clark</a>.</li>
<li>Pearson, Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSO#NYSE">PSO</a>) shares decreased 6.08% last week.</li>
<li>FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) stock declined 5.65%. The Board of Directors has appointed Sanoke Viswanathan as Chief Executive Officer, <a href="https://www.benzinga.com//node/45742153" target="_blank" rel="noreferrer noopener">effective early September 2025</a>.</li>
<li>Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) shares were down 5.38% last week.</li>
</ol>
Image Via Shutterstock

Equities

Large Cap

News

Movers

CIEN

DOCU

KVUE

LULU

TSLA

Tesla And Lululemon Are Among Top 10 Large-Cap Losers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?

<h3 class="wp-block-heading">New On The Block</h3>
Byron Allen's Allen Media Group has hired Moelis &amp; Company to explore a sale of its TV stations across 21 markets. The company spent over $1 billion acquiring Big Four network affiliates (ABC, NBC, CBS, FOX) over the past six years. 
It is now looking to cash out and reduce debt. Deadline <a href="https://deadline.com/2025/06/allen-media-group-hires-investment-bank-to-sell-tv-stations-1236420381/">reported</a> that the TV stations have received multiple offers. 
Also for sale: 
<ul class="wp-block-list">
<li>Jefferies is shopping around PatientPoint, a health marketing and ad agency, according <a href="https://www.axios.com/pro/health-tech-deals/2025/06/04/patientpoint-jefferies-sale">to</a> Axios. L Catterton, Littlejohn &amp; Co. and Transformation Capital are on the sell side. </li>
<li>Just three years ago, private equity firm One Equity Partners <a href="https://www.oneequity.com/news/one-equity-partners-completes-investment-in-infucare-rx-a-leading-home-infusion-therapy-provider/">completed</a> a strategic investment in infusion provider InfuCare. Today? It&#8217;s looking to get rid of it. According to Axios, JPMorgan is <a href="https://www.axios.com/pro/health-tech-deals/2025/06/03/infucare-one-equity-jpmorgan-sale">looking</a> for a buyer. </li>
<li>Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) received a <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report">bid exceeding $3 billion</a> from Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>). MoonLake turned down the initial offer, but talks are reportedly revived. The potential purchase signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.</li>
</ul>
<h3 class="wp-block-heading">Updates From The Block</h3>
<ul class="wp-block-list">
<li>Post Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) is forking over $880 million—including assumed debt—to buy 8th Avenue Food &amp; Provisions. That means brands like Ronzoni pasta will go back into Post&#8217;s pantry. <a href="https://www.wsj.com/articles/post-holdings-to-buy-ronzoni-pasta-owner-8th-avenue-food-cf8f454c?mod=deals_news_article_pos2">Per</a> The Wall Street Journal, the private-label brands originally got spun off into 8th Avenue in 2018 with help from private equity firm THL. Post plans to wipe out 8th Avenue's net debt and pick up the tab for all equity interests, including $111 million in finance leases. All in, the transaction is expected to cook up $15 million in annual synergies by the end of fiscal 2026. If Post closes by July 1, it expects 2026 to be more profitable (on an adjusted basis) than initially expected.</li>
</ul>
<ul class="wp-block-list">
<li>Rosebank Industries (LON: ROSE) is once again in talks to buy Electrical Components International (ECI), a wire harnesses manufacturer, for about $1.9 billion, Reuters reported. Rosebank was in talks to buy ECI in February but dropped the plans in March.</li>
</ul>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU. The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases. Sanofi will pay&nbsp;$129&nbsp;per share in cash, representing an equity value <a href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout">of roughly&nbsp;$9.1 billion</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) is acquiring a 51% stake in a new $3.4 billion tissue products joint venture with Kimberly-Clark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>), <a href="https://www.benzinga.com/m-a/25/06/45797473/tissue-titans-unite-suzano-kimberly-clark-form-3-4-billion-global-jv">paying $1.734 billion in cash</a>. Kimberly-Clark will retain a 49% stake. The Netherlands-based venture will produce and distribute toilet paper and facial tissues in 70 countries, with 22 factories across 14 countries, employing about 9,000 people. The facilities have an annual capacity of 1 million tonnes and generated $3.3 billion in net sales in 2024.</li>
</ul>
<h3 class="wp-block-heading">Off The Block</h3>
<ul class="wp-block-list">
<li>Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740112/robinhood-completes-200-million-bitstamp-deal-gains-access-to-500k-crypto-users-and-95-million-revenue-stream">completed its $200 million acquisition</a> of Bitstamp, a crypto exchange that had raised around $40 million from firms like Pantera Capital and Ripple.</li>
</ul>
<ul class="wp-block-list">
<li>Cactus Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) <a href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach">formed a joint venture</a> with Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), taking a 65% stake and operational control of Baker Hughes&#8217; Surface Pressure Control (SPC) business. Baker Hughes will retain a 35% stake. The new venture, separate from Cactus' current pressure control unit, will focus on international wellhead and production tree systems.</li>
</ul>
<ul class="wp-block-list">
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is <a href="https://www.benzinga.com/pressreleases/25/06/b45719054/guardian-pharmacy-services-expands-pacific-northwest-footprint-with-acquisition-of-washington-base" target="_blank" rel="noreferrer noopener">entering the Pacific Northwest market</a> via acquisition. Mercury Pharmacy Services, a provider of long-term care pharmacy solutions, agreed to a price, but <a href="https://www.benzinga.com/m-a/25/06/45723960/guardian-pharmacy-strengthens-us-footprint-with-new-seattle-area-acquisition">the amount remains undisclosed</a>.</li>
</ul>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
<ul class="wp-block-list">
<li>AI startup Builder.ai has filed for Chapter 7 bankruptcy in Delaware after creditors seized most of its cash, citing overstated 2024 sales projections—by a staggering 300%. Once valued at $1.5 billion, Builder.ai is now the biggest AI collapse since the ChatGPT-driven investment boom began. According <a href="https://www.bloomberg.com/news/articles/2025-06-05/builder-ai-files-for-bankruptcy-after-creditors-seize-accounts?sref=TBDibEcD">to</a> Bloomberg, the fallout was fueled by revelations that Builder.ai allegedly faked business with Indian social media firm VerSe Innovation to inflate revenues. VerSe co-founder Umang Bedi denies any wrongdoing, calling the claims "baseless and false."</li>
</ul>
<ul class="wp-block-list">
<li>Hooters closed some 30 corporate-owned restaurants and explained that it has <a href="https://www.businesswire.com/news/home/20250331979797/en/Hooters-of-America-Takes-Strategic-Action-to-Continue-its-Iconic-Legacy-Under-Pure-Franchise-Business-Model" target="_blank" rel="noreferrer noopener">no plans </a>to shut down any other locations. The Atlanta, Georgia-based restaurant chain went <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">bankrupt earlier this year</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Alex Jones may see his personal assets — including guns, cars, and homes — sold by the end of the year, according to the Houston Chronicle, <a href="https://www.houstonchronicle.com/news/houston-texas/texas/article/alex-jones-personal-assets-sales-bankruptcy-20361565.php">citing</a> a bankruptcy trustee. The potential sale would mark the nearing end of his two-and-a-half-year bankruptcy process. Jones, who created the far-right conspiracy theory website Infowars, filed for bankruptcy in 2022 after being ordered to pay nearly $1.5 billion to families of Sandy Hook shooting victims for defamation.</li>
</ul>
<h3 class="wp-block-heading">Notes From The Block</h3>
A studio's IP portfolio and game development pipeline are critical for video game investors. A major acquirer in the sector is GDEV Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>). The Cyprus-based company has made three M&amp;A deals and spent $100 million on studio acquisitions since 2022. 
This week, Andrey Fadeev drafted <a href="https://www.benzinga.com/m-a/25/06/45722621/gdevs-founder-ceo-evaluates-m-a-deals-using-these-5-metrics">a listicle of key metrics</a> GDEV uses for M&amp;A evaluation.
<ol class="wp-block-list">
<li>LTV/CAC Ratio – Measures how efficiently a studio converts user acquisition spend into revenue. A ratio above 1.0 indicates profitable user growth.</li>
<li>Retention Rates (D1, D7, D30) – Track user engagement over time. High retention signals strong gameplay and monetization potential. Benchmarks vary by genre.</li>
<li>ARPU/ARPPU – Indicate monetization efficiency. ARPU includes all users; ARPPU focuses on paying users. Higher ARPU justifies higher CAC.</li>
<li>DAU/MAU Ratio – Shows user engagement depth. A ratio above 20% is considered strong.</li>
<li>EBITDA – Reflects core operational profitability and financial health. High EBITDA margins show sustainable growth and efficiency.</li>
</ol>
In 2024, video game M&amp;A activity reached $27.3 billion, underscoring the sector's immense growth and investment appeal. C-suite executives would be wise to consider these metrics when searching for their next target. 
<a href="https://www.benzinga.com/markets/asset-sales/25/05/45702349/deal-dispatch-beauty-brand-behavioral-health-firms-hit-auction-block">For last week&#8217;s edition of Deal Dispatch, click here</a>.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45816311/conagra-sells-seafood-brands-for-55m-as-it-sharpens-focus-on-core-business">Conagra Sells Seafood Brands For $55M As It Sharpens Focus On Core Business</a></li>
</ul>
Image created using a photo from Shutterstock.

Asset Sales

BPMC

GDEV

GRDN

HOOD

KEYS

MLTX

POST

ROSE

SNOW

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) rolls up $3.4 billion in a tissue deal with Kimberly-Clark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>).
São Paulo, Brazil-based Suzano will pay Kimberly-Clark $1.734 billion in cash for its stake in the joint venture.
This newly formed company will produce and distribute products such as toilet paper and facial tissues <a href="https://www.benzinga.com/pressreleases/25/06/b45789210/suzano-and-kimberly-clark-announce-the-creation-of-a-global-tissue-company-operating-in-over-70-co" target="_blank" rel="noreferrer noopener">across 70 countries</a>.
Suzano will hold a 51% stake in the venture, while Kimberly-Clark will retain a 49% share.
The joint venture is incorporated in the Netherlands. It will employ around 9,000 people and encompass 22 manufacturing facilities across 14 countries in regions.
These sites collectively have a production capacity of roughly 1 million tonnes of tissue products annually. They have generated around $3.3 billion in net sales in 2024.
Also Read: <a href="https://www.benzinga.com/25/05/45170433/kimberly-clark-commits-2b-to-us-expansion-overhaul" target="_blank" rel="noreferrer noopener">Kimberly-Clark Commits $2 Billion For US Expansion Overhaul</a>
Additionally, the agreement grants Suzano a call option, allowing it to purchase Kimberly-Clark&#8217;s remaining 49% stake in the joint venture.
Post closure, Kimberly-Clark expects an estimated dilution of approximately 30 to 40 cents to adjusted EPS in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45788830/kimberly-clark-announces-major-step-forward-in-its-powering-care-transformation" rel="noreferrer noopener">the first full year after closing</a>.
The transaction is expected to be finalized by mid-2026, pending regulatory and governmental approvals, customary closing conditions, and the completion of Kimberly-Clark&#8217;s corporate restructuring.
Upon completion of the transaction, Suzano and Kimberly-Clark will formalize a joint venture agreement outlining their respective rights and responsibilities regarding the governance, ownership, operations, and management of the new company.
Kimberly-Clark CEO Mike Hsu said, &#8220;Following years of deliberate investments that have strengthened Kimberly-Clark and IFP, we are excited to expand our partnership with Suzano and focus Kimberly-Clark&#8217;s portfolio on our higher growth, higher margin businesses.&#8221;
As of March 31, Kimberly-Clark&#8217;s cash and equivalents at quarter <a href="https://www.benzinga.com/25/04/44921515/kimberly-clark-misses-q1-revenue-mark-trims-profit-guidance-as-supply-chain-costs-bite-hard" target="_blank" rel="noreferrer noopener">end was $563 million</a>.
Price Action: SUZ shares are up 6.24% at $9.36 on Thursday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44959233/kimberly-clark-analysts-slash-their-forecasts-following-weak-sales" target="_blank" rel="noreferrer noopener">Kimberly-Clark Analysts Slash Their Forecasts Following Weak Sales</a></li>
</ul>
Image: Shutterstock

Tissue Titans Unite: Suzano, Kimberly-Clark Form $3.4 Billion Global JV

Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) unveiled a sweeping overhaul on Thursday at the 2025 Deutsche Bank Global Consumer <a target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0000080424/995e4954-0a90-46da-8215-51b98f42f344.html" rel="noreferrer noopener">Conference</a>. It outlined a strategy to simplify operations and sharpen its focus on core growth areas.
The move is part of a broader effort to boost efficiency and enhance long-term value for shareholders.
The restructuring plan includes cost-cutting initiatives and the elimination of up to 7,000 roles, primarily targeting non-manufacturing functions.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45789179/top-3-consumer-stocks-youll-regret-missing-this-quarter." rel="noreferrer noopener">Top 3 Consumer Stocks You&#8217;ll Regret Missing This Quarter</a>
P&amp;G anticipates taking pre-tax charges ranging between $1 billion and $1.6 billion over the next two fiscal years, with about 25% of those being non-cash charges tied to asset write-downs.
Procter &amp; Gamble intends to streamline its portfolio by divesting underperforming brands and exiting select markets. It also plans to revamp its supply chain using automation and digital tools while reducing organizational layers to cut overhead and reinvest in brand development.
For <a target="_blank" href="https://www.benzinga.com/25/04/44984872/gillette-parent-procter-gamble-slides-on-q3-sales-decline-lowered-outlook" rel="noreferrer noopener">the third quarter</a>, the company&#8217;s organic revenue climbed 5%, driven mainly by pricing strategies. Net income grew 8% to $8.6 billion, while GAAP earnings per share reached $3.49. Core EPS rose 4% to $3.81, and free cash flow productivity remained above 100%.
P&amp;G expects flat all-in sales and 2% organic growth for fiscal 2025. It lowered adjusted EPS guidance and forecasted $200 million in headwinds from commodities and forex. Dividend and buyback plans remain unchanged.
Related: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45020318/what-is-the-tariff-risk-for-procter-gamble-analyst-calculates-trims-outlook" rel="noreferrer noopener">What Is The Tariff Risk For Procter &amp; Gamble? Analyst Calculates, Trims Outlook</a>
P&amp;G also flagged external risks, including inflation, currency volatility, and global geopolitical issues. Yet the company expressed confidence in its long-term growth outlook, pointing to rising e-commerce demand, ongoing innovation in premium offerings, and increased exposure to developing markets.
Related ETFs: Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>), Vanguard Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDC#NYSE">VDC</a>).
Price Action: PG shares are trading lower by 0.15% to $165.70 premarket at the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/45791216/citi-to-cut-3500-tech-jobs-in-china-in-global-restructuring-spree" target="_blank" rel="noreferrer noopener">Citi To Cut 3,500 Tech Jobs In China In Global Restructuring Spree</a></li>
</ul>
Photo via Shutterstock

Procter & Gamble To Eliminate 7,000 Roles, Divest Brands In New Restructuring Strategy

<ul>
<li>New joint venture will be the owner of Kimberly-Clark's international tissue assets, including 22 manufacturing facilities, approximately 9,000 employees, and marketing and selling regional and global brands, such as Kleenex, Scott and WypAll in over 70 countries.</li>
<li>The strategic partnership will integrate Suzano's industrial and operational expertise with Kimberly-Clark´s brand management and international experience across a range of markets.</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.suzano.com.br%2Fen&amp;esheet=54266377&amp;newsitemid=20250605515357&amp;lan=en-US&amp;anchor=Suzano&amp;index=1&amp;md5=52e38c7f5acfd6efcc32b04d73518baf">Suzano</a>, the world's largest pulp producer, and Kimberly-Clark, a global leader in the consumer staples industry, today announced the creation of a US$3.4 billion joint venture focused on the manufacture, marketing and distribution of consumer and professional tissue products, such as toilet paper, napkins, paper towels and facial tissues in over 70 countries. Suzano will acquire a 51 percent interest in the new entity, with Kimberly-Clark holding a 49 percent interest.
Suzano will pay Kimberly-Clark US$1.734 billion in cash for its 51 percent stake at the closing of the transaction, subject to certain customary post-closing purchase price adjustments. Closing of the transaction is contingent on, among other things, approval by regulatory and other governmental authorities, fulfillment of customary conditions precedent for transactions of this nature, and completion by Kimberly-Clarkof a corporate reorganization of its Consumer Tissue and Professional business unit. The transaction is expected to close in mid-2026 and involves approximately 9,000 employees.
The new business will be a company incorporated in the Netherlands and will include 22 manufacturing facilities located in 14 countries across Europe, Asia, including Southeast Asia, the Middle East, South America, Central America, Africa, and Oceania. Collectively, these facilities have an installed capacity to produce approximately 1 million tonnes of tissue a year. The assets to be included in the new joint venture generated net sales in 2024 of approximately US$3.3 billion.
Kimberly-Clark will retain its consumer tissue and professional businesses in the United States and its interests in existing joint ventures in Mexico, South Korea and Bahrain, among other countries.

Suzano, Kimberly-Clark Form $3.4B Global Tissue Joint Venture

<a href="https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;" title="https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;">https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;</a>
<a href="https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;gaa_ts=68417938&amp;gaa_sig=XyWw5OpGvoofdTyiG2em5A_2d9_UyLB2-_F6t3jzNLB5rcYATr0BmKEphk4lteRrOHONpiTBJIhBhORH8pDuTw%3D%3D" title="https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;gaa_ts=68417938&amp;gaa_sig=XyWw5OpGvoofdTyiG2em5A_2d9_UyLB2-_F6t3jzNLB5rcYATr0BmKEphk4lteRrOHONpiTBJIhBhORH8pDuTw%3D%3D">https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;gaa_ts=68417938&amp;gaa_sig=XyWw5OpGvoofdTyiG2em5A_2d9_UyLB2-_F6t3jzNLB5rcYATr0BmKEphk4lteRrOHONpiTBJIhBhORH8pDuTw%3D%3D</a>

The Wall Street Journal Reported Wednesday, Kimberly-Clark Nears Roughly $3.5B Sale of International Tissue Business

Ticker symbol to remain "KMB"
DALLAS, May 19, 2025 /PRNewswire/ -- Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>), a global leader in the consumer staples industry, announced today that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq&nbsp;Global Select Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). Kimberly-Clark expects that its common stock will cease trading on the NYSE at market close on Thursday, May 29, 2025, and will commence trading on Nasdaq on Friday, May 30, 2025.

Kimberly-Clark To Voluntarily Transfer Its U.S. Stock Exchange Listing To Nasdaq From NYSE; To Commence Trading On Nasdaq On May 30, 2025

Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) today announced that Russ Torres, President, North America, has been promoted to President and Chief Operating Officer, effective immediately.&nbsp;

Kimberly-Clark Promotes Russ Torres To President And COO, Effective Immediately

Kimberly-Clark Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) is set to<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45146999/kimberly-clark-announces-plans-to-invest-over-2-billion-to-expand-us-manufacturing-accelerate-inno" rel="noreferrer noopener"> invest upwards of $2 billion</a> into its North American business over the next five years, marking its largest U.S.-based expansion effort in more than 30 years.
The initiative comes amid growing consumer demand for its popular household products, including Huggies, Kleenex, and Cottonelle.
Central to this plan are two major buildouts: a production facility in Warren, Ohio, and an upgrade to the Beech Island, South Carolina, location, which will feature a fully automated logistics hub.
These developments are designed to increase manufacturing capacity, enhance technological advancement, and support the company's long-term growth objectives.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45135213/mcdonalds-q1-revenue-decline-34-as-war-in-the-middle-east-bites-stock-dips" rel="noreferrer noopener">Middle-East Tensions And Consumer Uncertainty Bites McDonald's Q1 Revenue</a>
"This landmark investment represents a strategic bet on the American consumer and our ability to drive innovation-led sustainable growth for Kimberly-Clark,"&nbsp;said&nbsp;Group President,&nbsp;Kimberly-Clark North America, Russ Torres. &nbsp;
The new plant in Ohio will act as a central manufacturing site for the Northeast and Midwest. Positioned to serve approximately 117 million people, the one-million-square-foot complex will bolster Kimberly-Clark's personal care segment by assimilating advanced production systems and boosting the pace of product development.
In South Carolina, Kimberly-Clark will build a high-tech distribution center next to its biggest U.S. plant, using robotics and AI to speed up delivery and enhance shipping efficiency.
Together, these projects are expected to generate over 900 skilled jobs in fields such as industrial automation and advanced manufacturing.
Construction is slated to begin in May 2025 and could take up to three years to complete. Kimberly-Clark's <a target="_blank" href="https://www.benzinga.com/25/04/44921515/kimberly-clark-misses-q1-revenue-mark-trims-profit-guidance-as-supply-chain-costs-bite-hard" rel="noreferrer noopener">first-quarter sales </a>were down 6% to $4.84 billion.
Price Action: KMB shares traded lower by 0.18% at $129.64 at last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45074719/levi-strauss-shareholders-stand-by-dei-policy-amid-political-pushback" target="_blank" rel="noreferrer noopener">Levi Strauss Shareholders Stand By DEI Policy Amid Political Pushback</a></li>
</ul>
Photo via Shutterstock

General

Kimberly-Clark Commits $2 Billion For US Expansion Overhaul

<a href="https://www.wsj.com/business/kimberly-clark-kleenex-investing-2-billion-manufacturing-us-503c4c7d">https://www.wsj.com/business/kimberly-clark-kleenex-investing-2-billion-manufacturing-us-503c4c7d</a>

'Kimberly-Clark to Invest $2 Billion in U.S. Manufacturing Sites'- WSJ

On April 29, a recent SEC filing unveiled that Katy Chen, President at Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) made an insider sell.
What Happened: Chen opted to sell 1,794 shares of Kimberly-Clark, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000055785/000122520825004500//Archives/edgar/data/55785/000122520825004500/0001225208-25-004500-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The transaction's total worth stands at $234,544.
At Wednesday morning, Kimberly-Clark shares are up by 0.82%, trading at $131.62.
<h3>All You Need to Know About Kimberly-Clark</h3>
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, PullUps, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
<h3>Unraveling the Financial Story of Kimberly-Clark</h3>
Decline in Revenue: Over the 3 months period, Kimberly-Clark faced challenges, resulting in a decline of approximately -6.0% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 35.81%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Kimberly-Clark's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.71.
</li>
</ul>
Debt Management: Kimberly-Clark's debt-to-equity ratio stands notably higher than the industry average, reaching 6.58. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 17.79 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 2.22 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 12.75 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000055785">Check Out The Full List Of Kimberly-Clark's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Katy Chen Implements A Sell Strategy: Offloads $234K In Kimberly-Clark Stock

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) can still go lower. &#8220;It's really well-run, so don't take this the wrong way, but the airlines are wrong to own right here because people think we're going into a travel recession.&#8221;
On the earnings front, <a href="https://www.benzinga.com/quote/ALK">Alaska Air Group</a> reported worse-than-expected first-quarter financial results on April 23 and issued second-quarter adjusted EPS guidance below estimates.
Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) did not make the quarter, Cramer said. &#8220;I was a little bummed out. Let's wait 'til it goes lower.&#8221;
On April 22, Kimberly-Clark posted first-quarter adjusted earnings per share of $1.93, beating the analyst consensus estimate of $1.89. Quarterly sales of $4.84 billion (down 6%) missed the street view of $4.88 billion.
CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is &#8220;terrific&#8221; for the long term, Cramer said. &#8220;We had to take some profits the other day, too, because it just got too big.&#8221;
CrowdStrike showcased Charlotte AI Agentic Response and Charlotte AI Agentic Workflows on Monday, marking progress in modern SOC operations.
When asked about Dillard&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>), he said, &#8220;You're going to be struggling to make money in any other retailer other than Costco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>). I don't think Dillard's is a place to be.&#8221;
According to recent news, Dillard&#8217;s amended and extended its $800 million senior secured revolving credit facility on March 17.
Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) is &#8220;not great, not bad,&#8221; Cramer said. "This is technology all made in America. So, I think you're ok.&#8221;
Nextracker, meanwhile, will announce its fourth quarter fiscal 2025 financial results after the closing bell on Wednesday, May 14.
Price Action:
<ul>
<li>Alaska Air shares gained 1.6% to settle at $43.70 on Tuesday.</li>
<li>Kimberly-Clark shares fell 0.3% to close at $130.55 during the session.</li>
<li>CrowdStrike shares gained 1.9% to settle at $430.99 on Tuesday.</li>
<li>Dillard's shares gained 1% to close at $343.15.</li>
<li>Nextracker shares slipped 0.3% to close at $43.07 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a></li>
</ul>
Photo: Shutterstock

Media

COST

CRWD

Jim Cramer: This Tech Stock Is 'Not Great, Not Bad', Alaska Air Can Still Go Lower

These twelve large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) stock tumbled 14.92% after the company issued FY25 adjusted EPS guidance with its midpoint below estimates. Analysts changed <a href="https://www.benzinga.com//node/45013364" target="_blank" rel="noreferrer noopener">their price forecasts</a>.</li>
<li>Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) shares dipped 12.43% after the company reported worse-than-expected results and lowered its FY25 EPS guidance. Several analysts <a href="https://www.benzinga.com//node/44965915" target="_blank" rel="noreferrer noopener">lowered their price forecasts</a>.</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) stock plummeted 11.95% after it reported financial results <a href="https://www.benzinga.com//node/44995337" target="_blank" rel="noreferrer noopener">and missed its EPS estimate</a>.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) shares fell 11.17% last week following the <a href="https://www.benzinga.com//node/44995935" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Watsco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) shares dipped 9.98% after the company reported first-quarter results and <a href="https://www.benzinga.com//node/44945784" target="_blank" rel="noreferrer noopener">missed its EPS and sales estimates</a>. Analysts <a href="https://www.benzinga.com/quote/wso/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>Gold Fields (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) shares decreased 9.13%, probably because gold prices dropped after President Trump said he had no intention of firing Fed Chair Powell and indicated that the final tariff rate with China would be &#8220;substantially&#8221; lower than the current 145%.</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) stock fell 8.59% after the company reported financial results and missed its adjusted <a href="https://www.benzinga.com//node/45003204" target="_blank" rel="noreferrer noopener">EPS and revenue estimates</a>.</li>
<li>AngloGold Ashanti PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) shares fell 8.44%, probably because gold prices dropped after President Trump said he had no intention of firing Fed Chair Powell and indicated that the final tariff rate with China would be &#8220;substantially&#8221; lower than the current 145%.</li>
<li>Ryan Specialty Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) stock was down 8.17%. The company inked a deal to acquire certain assets of USQRisk <a href="https://www.benzinga.com//node/44910617" target="_blank" rel="noreferrer noopener">Holdings for an undisclosed amount</a>.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) stock fell 7.99% last week after the company reported first-quarter results. Several analysts <a href="https://www.benzinga.com/quote/TYL/analyst-ratings" target="_blank" rel="noreferrer noopener">lowered their price forecasts</a>.</li>
<li>Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) stock declined 7.84% after it reported weaker-than-expected first-quarter sales, and several <a href="https://www.benzinga.com//node/44959233" target="_blank" rel="noreferrer noopener">analysts slashed their price forecast</a>.</li>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares decreased 7.81%. The company reported disappointing first-quarter results last week, and <a href="https://www.benzinga.com//node/44913470" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
</ol>
Photo by Ken Wolter via Shutterstock

Earnings

ERIE

RYAN

TMUS

UnitedHealth, T-Mobile And Fiserv Are Among Top 12 Large-Cap Losers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?

<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Jack in the Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) is exploring strategic options for Del Taco, including a potential sale, just two years after acquiring it for $585 million. According <a href="https://www.bloomberg.com/news/articles/2025-04-23/jack-in-the-box-weighs-sale-of-del-taco-restaurant-chain?srnd=phx-deals&amp;sref=TBDibEcD">to</a> Bloomberg, the fast-food chain could fetch up to $200 million. The company is working with Bank of America on the process and plans to close 150 to 200 underperforming restaurants as part of <a href="https://www.benzinga.com/topic/fast-food">a broader restructuring</a>.</li>
</ul>
<ul>
<li>Billy McFarland, the infamous mastermind behind the spectacular dumpster fire known as Fyre Festival, is back. After conning the rich and famous (and some unlucky Instagram influencers) out of millions and earning himself nearly four years behind bars, McFarland was supposedly prepping for another Fyre event. With just a month to go before round two was set to launch, he's now trying to auction off the "Fyre" brand to the highest bidder, <a href="https://www.instagram.com/p/DIzDz6exph0/?hl=en">saying</a>: "This brand is bigger than any one person" — this coming from the guy who turned it into a global meme against the gullible. </li>
</ul>
<h2 class="wp-block-heading">Updates On The Block</h2>
<ul>
<li>UPS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) is <a href="https://about.ups.com/us/en/newsroom/press-releases/our-strategy/ups-to-acquire-andlauer-healthcare-group-for--1-6-billion--stren.html">acquiring</a> Canadian healthcare logistics firm Andlauer Healthcare Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AND#TSX">AND</a>) for approximately $1.6 billion, paying C$55 per share—a 31% premium. The deal, expected to close by year-end, could pressure rivals like FedEx and DHL to expand their presence in the higher-margin healthcare sector. Notably, Andlauer's CEO, Michael Andlauer, also owns the NHL's Ottawa Senators, who are currently down 2-0 in a series against the Toronto Maple Leafs.</li>
</ul>
<ul>
<li>Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) has short-listed three strategic bidders for its global tissue unit, which could sell for around $4 billion. The unit generates approximately $500 million in annual EBITDA, and binding bids are expected by mid-May, according to Reuters.</li>
</ul>
<ul>
<li>Clothing brand Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) previously received a $677-million take-private bid from WHP Global. The brand is also considering a takeover bid from private equity-backed Authentic Brands Group. ABG backers include CVC Capital Partners, General Atlantic, HPS Investment Partners and Leonard Green &amp; Partners.</li>
</ul>
<ul>
<li>Merck KGaA is in late-stage talks to buy SpringWorks Therapeutics for around $3.5 billion, or approximately $47 per share. A deal could be announced as soon as Monday, Bloomberg reported. The deal would support Merck's pharma division, which is facing a patent expiration for a multiple sclerosis drug.</li>
</ul>
<ul>
<li>Tencent Music is reportedly <a href="https://www.bloomberg.com/news/articles/2025-04-25/tencent-music-is-said-in-talks-to-buy-ximalaya-for-2-4-billion?srnd=phx-deals">in</a> discussions with China-based startup Ximalaya. The price tag is roughly $2.4 billion in a cash-and-stock deal. A deal could be finalized in the coming weeks, though discussions are ongoing. Ximalaya, backed by Tencent, Baidu and Sony Music, had 303 million monthly active users in 2023 and previously delayed a planned Hong Kong IPO. Tencent Music, which owns QQ Music, Kugou, Kuwo and WeSing, went public in the U.S. in 2018 and now has a market cap of about $20.6 billion.</li>
</ul>
<ul>
<li>European regulators <a href="https://www.ft.com/content/f06fa20d-a76b-494a-a09b-224e4d210db4">are</a> preparing to investigate Universal Music Group's proposed $775 million acquisition of Downtown Music Holdings, the Financial Times reports. The update follows antitrust concerns raised in Austria and the Netherlands. Although the deal didn&#8217;t meet EU-wide merger notification thresholds, the European Commission accepted requests to review it due to potential impacts on competition within the Single Market. Universal announced the acquisition via its Virgin Music division in December.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul>
<li>Bertucci's is going back, not for seconds, but for thirds. The casual dining franchise known for its pizza is <a href="https://www.courtlistener.com/docket/69938534/1/bertuccis-restaurants-llc/">headed</a> for Chapter 11 bankruptcy. This would be the third time since 2018. The chain closed 7 of its 22 locations before filing, leaving 15 operating restaurants across six states. The Northborough, Massachusetts-based franchise has downsized significantly from 56 locations in 2018. It is now exploring a fast-casual spinoff, Bertucci's Pronto, to adapt to shifting consumer preferences. The company also pointed to broader struggles in the dining sector, citing the bankruptcies of Red Lobster <a href="https://www.benzinga.com/m-a/24/11/41700829/deal-dispatch-tgi-fridays-goes-bankrupt-bhp-backtracks-comments-and-more-m-a-news">and TGI Fridays</a>.</li>
</ul>
Check out last week&#8217;s edition of the <a href="https://www.benzinga.com/news/asset-sales/25/04/44884363/deal-dispatch-metaverse-23andme-burgerking-franchisee">Deal Dispatch</a>.

JACK

TSX:AND

Deal Dispatch: Jack In The Box To Dump Del Taco, Fyre Brand Hits Auction Block, Bertucci's Bites Bankruptcy Bullet (Again)

Barclays analyst Lauren Lieberman maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Equal-Weight and lowers the price target from $139 to $135.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Kimberly-Clark, Lowers Price Target to $135

Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) reported weaker-than-expected first-<a href="https://www.benzinga.com/quote/kmb/earnings">quarter sales on Tuesday</a>.
Quarterly adjusted earnings per share totaled $1.93, beating the analyst consensus estimate of $1.89. Quarterly sales of $4.84 billion (down 6%) missed the street view of $4.88 billion.
"The current environment will now mean greater costs across our global supply chain versus our expectations at the beginning of the year," warned Kimberly-Clark CEO Mike Hsu.
The company now expects its 2025 Adjusted Operating Profit to be flat to positive on a constant-currency basis. Last year, the expectation was high single-digit growth on a constant currency basis.
Reported net sales are expected to face a 200 basis point hit from currency translation, improving from the earlier estimate of 300 basis points. Additionally, divesting the PPE business and exiting the U.S. private label diaper segment will weigh on sales by another 240 basis points.
Kimberly-Clark shares fell 4.1% to trade at $132.30 on Wednesday.
These analysts made changes to their price targets on Kimberly-Clark following earnings announcement.
<ul>
<li>Evercore ISI Group analyst Javier Escalante maintained Kimberly-Clark with an Outperform rating and lowered the price target from $168 to $155.</li>
<li>Piper Sandler analyst Korinne Wolfmeyer maintained Kimberly-Clark with an Overweight rating and lowered the price target from $158 to $156.</li>
<li>RBC Capital analyst Nik Modi maintained Kimberly-Clark with an Outperform rating and lowered the price target from $165 to $162.</li>
</ul>
Considering buying KMB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23132120/image-140-1024x587.png" alt="" class="wp-image-884845" style="width:587px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23132120/image-140-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23132120/image-140-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23132120/image-140-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23132120/image-140.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44950904/tesla-to-303-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Kimberly-Clark Analysts Slash Their Forecasts Following Weak Sales

RBC Capital analyst Nik Modi maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Outperform and lowers the price target from $165 to $162.

RBC Capital Maintains Outperform on Kimberly-Clark, Lowers Price Target to $162

Piper Sandler analyst Korinne Wolfmeyer maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Overweight and lowers the price target from $158 to $156.

Piper Sandler Maintains Overweight on Kimberly-Clark, Lowers Price Target to $156

Ratings for Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Kimberly-Clark and provided 12-month price targets. The average target is $148.67, accompanied by a high estimate of $165.00 and a low estimate of $131.00. This current average reflects an increase of 1.6% from the previous average price target of $146.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1745416820_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Kimberly-Clark is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Javier Escalante &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $155.00&#x7C;$168.00 &#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $146.00&#x7C;$134.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $165.00&#x7C;$165.00 &#x7C; 
&#x7C;Andrea Teixeira &#x7C;JP Morgan &#x7C;Raises &#x7C;Underweight &#x7C; $131.00&#x7C;$124.00 &#x7C; 
&#x7C;Chris Carey &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $140.00&#x7C;$130.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $144.00&#x7C;$138.00 &#x7C; 
&#x7C;Korinne Wolfmeyer &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $158.00&#x7C;$161.00 &#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $134.00&#x7C;$132.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $165.00&#x7C;$165.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kimberly-Clark. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Kimberly-Clark compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Kimberly-Clark's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Kimberly-Clark's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KMB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kimberly-Clark analyst ratings.</a>
<h2>Discovering Kimberly-Clark: A Closer Look</h2>
With more than half of sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, PullUps, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, which partners with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
<h3>Key Indicators: Kimberly-Clark's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Kimberly-Clark faced challenges, resulting in a decline of approximately -0.85% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Kimberly-Clark's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 9.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kimberly-Clark's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 42.07% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Kimberly-Clark's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.65%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Kimberly-Clark's debt-to-equity ratio stands notably higher than the industry average, reaching 9.02. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Kimberly-Clark's Future

Evercore ISI Group analyst Javier Escalante maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Outperform and lowers the price target from $168 to $155.

Comments

Kimberly-Clark

Noticias

Últimas noticias sobre Kimberly-Clark (NASDAQ:KMB) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL